Pre-Clinical Assets
•In May 2026, Lexeo will present preclinical data for LX2022 at the ASGCT Annual Meeting, demonstrating proof‑of‑concept efficacy for TNNI3 replacement in a newly developed porcine model of hypertrophic cardiomyopathy. This novel model closely recapitulates severe disease physiology and mortality and was specifically developed by Lexeo to evaluate TNNI3‑targeted therapies. TNNI3‑related disease is estimated to account for approximately 1-3% of genetic cardiomyopathies.
Corporate Updates
•Appointed Laura Sepp Lorenzino, Ph.D., as an independent, non-executive director to the Board of Directors. Laura was the former Chief Scientific Officer at Intellia Therapeutics and previously held senior research leadership roles at Alnylam Pharmaceuticals and Vertex Pharmaceuticals. She currently serves on the boards of AskBio, Taysha Gene Therapies, Ursa Medicines, the American Society of Gene & Cell Therapy (ASGCT) and the Oligonucleotide Therapeutics Society, and contributes to multiple scientific advisory boards including Inverna Therapeutics, Thermo Fisher Scientific, Arsenal Capital Partners and the UK Nucleic Acid Therapy Accelerator.
First Quarter 2026 Financial Results
•Cash Position: As of March 31, 2026, cash, cash equivalents, and investments in marketable securities were $227.6 million, which Lexeo believes will be sufficient to fund operations into 2028.
•Research & Development Expenses: Research and Development expenses were $15.7 million for the three months ended March 31, 2026, compared to $17.2 million for the three months ended March 31, 2025.
•General & Administrative Expenses: General and Administrative expenses were $6.6 million for the three months ended March 31, 2026, compared to $16.6 million for the three months ended March 31, 2025.
•Net Loss: Net loss was $20.2 million or $0.25 per share (basic and diluted) for the three months ended March 31, 2026, compared to $32.7 million or $0.99 per share (basic and diluted) for the three months ended March 31, 2025.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA), LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs and the timing for receipt and announcement of data from its clinical trials, the timing and likelihood of potential regulatory developments and approval, expectations regarding the time period over which Lexeo’s capital resources will be sufficient to fund its anticipated operations and estimates regarding Lexeo’s financial condition. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Annual Report on Form 10-K for the annual period ended December 31, 2025, filed with the SEC on March 30, 2026, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
Media Response:
